ISSN: 2278-2648

International Journal of Research in Pharmacology & Pharmacotherapeutics (IJRPP)

IJRPP |Vol.13 | Issue 4 | Oct - Dec -2024

www.ijrpp.com

DOI : https://doi.org/10.61096/ijrpp.v13.iss4.2024.631-635

Review

A Comprehensive Review On Cancer Vaccines

Praveen Kumar Dasari*, Kumar Raja Jayavarapu, E. Krishna Kumari, D. Prameela Rani, P. Pavan Kumar, P. Haritha, G. Durga

Mother Teresa Pharmacy College, Sathupally, Khammam, Telangana, India.

*Author for Correspondence: Dr. Praveen Kumar Dasari
Email: drdppharma@gmail.com

Published on: 19 Nov 2024

Published by:
Dr Sriram Publications

2024| All rights reserved.

Creative Commons Attribution 4.0 International License.

Abstract

Various stages of cancer vaccines, including peptide-based, dendritic cell-based, viral vector-based, DNA, and mRNA vaccines, their potential application in hepatocellular carcinoma (HCC) management. This review also addresses the dominant challenges in vaccine development, such as cancer heterogeneity and the need for identifying tumor-specific antigens. The action of cancer vaccines in reshaping the immune environment within HCC, fostering durable immune memory, and their potential in combination therapies. The review also examines the clinical trials and emphasizes the necessity for more extensive research to optimize vaccine design and patient selection criteria. Resulted with future perspectives, highlighting the significance of personalized therapies, innovative antigen delivery platforms, immune stimulant agents, and predictive biomarkers in revolutionizing HCC treatment. The review also carries clinical trials and emphasizes the necessity for more preventive research to optimize vaccine design and patient selection criteria. We conclude with outlook, feature the significance of personalized therapies, innovative antigen delivery platforms, immune stimulant agents, and predictive biomarkers in revolutionizing HCC control. This review explains the potential of cancer vaccines as a promising therapeutic category for hepatocellular carcinoma (HCC), a prevalent and deadly cancer.

Keywords: DNA vaccines; hepatocellular carcinoma; immunotherapy; mRNA vaccines; peptide-based vaccines; viral vector-based vaccines.

INTRODUCTION

Cancer vaccines are managed to the patients to kill cells by increase of the immune response of patients themselves. Vaccination treated the various functions of the resistant effector activated by directly target and kill tumor cells as well as spare normal cells. It can be used to prevent further development of advanced cancers and recurrent cancers as compare to conventional precaution. Vaccines are made from tumor cells, cell parts,

and pure immune trigger along with other cells called additives which add even more to the immune response. They can be divided into several stages, including cell, protein-peptide, and genetic vaccines. There are still challenges to the development of an effecience being cancer vaccine and several complex therapeutic vaccination advance towards are valuated in clinical trials.

Types

The main type of cancer vaccines

Cell-based vaccines include cancer cells or cancer cell lysates. Cancer cells from the patient are predicted to contain the greatest spectrum of relevant antigens, but this approach is expensive and often requires too many tumor cells from the patient to be effective. Using a combination of established tumor cell lines that resemble the patient's tumor can overcome these barriers, but this approach has yet to be effective. Canvaxin, which incorporates three melanocarcinoma cell lines, failed phase III clinical trials. Another cell-based vaccine category involves alike dendritic cells (dendritic cells derived from the patient) to which tumor antigens are added. In this category, the antigen-presenting dendritic cells directly stimulate T-cells rather than relying on processing of the antigens by cell vaccine, which only improves the survivality by four months. The efficacy of dendritic cell vaccines may be limited due to APCs after the vaccine is delivered. The best known dendritic lty in getting the cells to migrate to lymph nodes and treated with T-cells.

Peptide-based vaccines usually consist of cancer specific-epitopes and often require an adjuvant to tonic the immune system and enhance antigenicity.Examples of these antigenic determinant include Her2 peptides, such as GP2 and NeuVax. However, this approach requires MHC profiling of the patent because of MHC restriction. The need for MHC profile selection can be overcome by using longer peptides cleanprotein, which are then processed into epitopes by APCs.

Gene-based vaccines are composed of the nucleic acid encrypting for the gene. The gene is then communicated with APCs and the resulting protein product is processed into epitopes. Delivery of the gene especially challenging for this type of vaccine.]At least one drug candidate, mRNA-4157/V940, is look into newly developed mRNA vaccines for use in this application.



Fig 1: Common vaccine components

Preparation of vaccines

Cancer vaccines are made from the persons own cancer cells are from cells that are grown in a laboratory. The cancer cells are treated with heat or radiation, then they become inactive and can be used for vaccine preparation. Definite proteins may then be grasp from the cancer cells and used to make a cancer vaccine. Often a cancer vaccine will also accomdate substances that are already called to boost the immune system, such as BCG.



Fig 2: Diagrammatic representation of cancer vaccine preparation.



Fig 3: Mechanism of action Vaccine

Cancer vaccines which are currently under the clinical trials,

Onyvax [a monoclonal antibody 1057D7 anti idiotype vaccines]

- It is used for the treatment of advanced colorectal adenocarcinoma.
- The vaccine is administered endemic together with BCG vaccine or intravenously together with the alum adjuvant

ONCOvax

- Autologus vaccine for stage 2 colon cancer.
- Received acceleration status from FDA in 2006

Study:

- 254 patients recived either onco vax or placebo.
- Improves 5 years of survival and recurrence free interval.
- 57 percent risk reduction

Cancer VAX

- It is being used together with the surgical treatment in the treatment of melanoma 3 stage
- To increase the cellular immune response, this vaccine is given along with the BCG vaccine.

GP 100 and MART 1
A vaccine therapy using tyrosine, GP100 and MART 1 peptidase together with the alum adjuvant is being used for the treatment of the patients with 2B, 2C, OR 4 coetaneous melanoma or stage 3,4 mucosal melanoma.
Researchers are preventively trying to overcome hurdles in the making of these vaccines.

Role of adjuvents in cancer vaccines

- Substances known as adjuvant are often added to boost their ability to induce potent anti cancer immune response.
- Some microbes, such as the bacterium Bacillus Calmette Guerin. [BCG]
- BCG is used to treat early-stage bladder cancer.it is a liquid put into the bladder together with cather
- Treatment with BCG vaccines can cause:
  Fever
  Chills
  Fatigue
- It also can cause burning feelings in the bladder.

Other drugs used to treat cancer vaccines

Thalidomide
Treatment for multiple myeloma.
Lenalidomide
Newer drug, treatment for multiple myeloma.
Bacille calmetteguerien

- Treatment of superficial forms of vesicle cancer
- Colorectal cancer
- Lung cancer
- Melanoma

Medicinal mushrooms
Aspricus substances anticancer properties.

Dose and administration

- For intravenous use only
- Administration three doses at approximately 2 weeks intervals
- Premedicate patients with oral acetaminophen and anti histamine
- Infuse sipuleucel T intravenously over 60 minutes

Applications

Cancer vaccines can help treat cancers that have already developed by teaching the immune system to recognize and destroy cancer cells. Cancer vaccines can:
Delay or stop cancer cell growth
Shrink tumors
Prevent cancer from returning
Eliminate cancer cells that other treatments have not killed
Preventing infections
Improving anticancer drug efficacy.

CONCLUSION

In cancer vaccine-related research is moving from preclinical study and clinical study to clinical utilization, and the number of related publications will continue to surge over the next years. The United States has the largest portion of research in this field and the highest quality and influence of articles and plays a key role in this field. Presently, cancer vaccine research is focused on how to minimize clinical benefits, immune checkpoint inhibitors, tumour microenvironment, dendritic cells, and Tcell suppressor may be the future research quality. Cancer vaccines represent a promising path in the fight against cancer, harnessing the power of the immune system to prevent tumor growth, recurrence, or changeover while enhancing its ability to recognize and eliminate cancer cells. The complex composition of TMEs and the diverse reaction they elicit play a critical role in determining treatment outcomes. The

activation of T cells is vital for effective immune reactions against cancer, while B cells contribute to both tumor suppression and promotion. NK cells hold the potential to eliminate cancer cells but face challenges within the immunosuppressive TME. DCs play a critical role in immune trigger presentation and T cell activation but may be impaired by cancer -derived factors. Neutrophils and TAMs exhibit dynamic roles, capable of switching connecting pro-cancer and anticancer states, influencing cancer initiation and development. comprehensive the complex interactions within TMEs are crucial for designing effective cancer vaccines. Transporting methods and the inclusion of assistant have proven pivotal in optimizing cancer vaccine success. Various transporting approaches, such as peptide-based, nucleic acid-based, protein-based, viral vector-based, and DC-based vaccines, offer distinct advantages and challenges that need to be considered for successful implementation. The meshing of assistant, such as TLR agonists, cytokines, and immune checkpoint inhibitors, enhances immune responses and promotes sustained immune activation, further augmenting vaccine efficacy.

REFERENCES

1. Moore, Z.S.; Seward, J.F.; Lane, J.M. Smallpox. Lancet 2006, 367, 425–435.
2. Roden, R.B.S.; Stern, P.L. Opportunities and challenges for human papillomavirus vaccination in cancer. Nat. Rev. Cancer 2018, 18, 240–254.
3. Pol, S. Hepatitis: HBV vaccine—The first vaccine to prevent cancer. Nat. Rev. Gastroenterol. Hepatol. 2015, 12, 190–191.
4. Chodon T.; Koya, R.C; Odunsi, K. Active Immunotherapy of Cancer. Immunol. Investig. 2015: 44, 817–836.
5. Saxena, M.; van der Burg, S.H.; Melief, C.J.M.; Bhara(d), N. Therapeutic cancer vaccines. Nat. Rev. Cancer. 2021, 21, 360–378.
6. Lu, C.; Liu, Y.; Ali, N.M.; Zhangguo, B.; Cui, X. The role of innate resistance cells in the tumor microenvironment and research progress in anti-tumor therapy. Front. Immunol. 2023, 13, 1039260.
7. Sun, B.; Hyun, H.; Li, L.T.; Contrive, A.Z. Harnessing nanomedicine to overcome the immune suppressant tumor microenvironment. Acta Pharmacol. Sin. 2020, 41, 970–985.
8. Kleponis, J.; Skelton, R.; Zheng, L. Fueling the engine and releasing the break: Combinational therapy of cancer vaccines and immunity checkpoint inhibitors. Cancer Biol. Med. 2015, 12, 201–208.
9. Kang, W.; Feng, Z.; Luo, J.; He, Z.; Liu, J.; Wu, J.; Rong, P. Tertiary Lymphoid Structures in Cancer: The Double-Edged Sword Role in Antitumor Immunity and Potential Therapeutic Induction Strategies. Front. Immunol. 2021, 12, 689270.
10. Kim, S.K.; Cho, S.W. The Evasion Mechanisms of Cancer resistance to and Drug Intervention in the Tumor Microenvironment. Front. Pharmacol. 2022, 13, 868695.
11. Hiam-Galvez, K.J.; Allen, B.M.; Spitzer, M.H. Systemic immunity in cancer. Nat. Rev. Cancer 2021, 21, 345–359.
12. Roche, P.A.; Furuta, K. The ins and outs of MHC class II-mediated immune trigger processing and presentation. Nat. Rev. Immunol. 2015, 15, 203–216.
13. Neefjes, J.; Jongsma, M.L.M.; Paul, P.; Bakke, O. Towards a systems understanding of MHC class i and MHC class II antigen presentation. Nat. Rev. Immunol. 2011, 11, 823–836.
14. Gaudino, S.J.; Kumar, P. Cross-talk between immune trigger presenting cells and T cells impacts intestinal homeostasis, bacterial infections, and tumorigenesis. Front. Immunol. 2019, 10, 422031.
15. Luo, Y.; Kanai, M.; Choi, W.; Li, X.; Sakaue, S.; Yamamoto, K.; Ogawa, K.; Gutierrez-Arcelus, M.; Gregersen, P.K.; Stuart, P.E.; et al. A high-resolution HLA reference panel capturing global population diversity enables origins fine-mapping in HIV host response. Nat. Genet. 2021, 53, 1504–1516.
16. Carlberg, C.; Velleuer, E. Molecular Immunology: How Science Works; Springer Nature: Berlin/Heidelberg, Germany, 2022; ISBN 9783031040252.
17. Hilligan, K.L.; Ronchese, F. Antigen presentation by dendritic cells and their instruction of CD4+ T helper cell responses. Cell. Mol. Immunol. 2020, 17, 587–599.
18. Eiz-Vesper, B.; Schmetzer, H.M. Antigen-presenting cells: Potential of proven und new players in immune therapies. Transfus. Med. Hemotherapy 2020, 47, 429–431.
19. Saxena, V.; Li, L.; Paluskievicz, C.; Kasinath, V.; Bean, A.; Abdi, R.; Jewell, C.M.; Bromberg, J.S. Role of lymph node stroma and milieu in T cell tolerance. Immunol. Rev. 2019, 292, 9–23.
20. Jung, Y.; Riven, I.; Feigelson, S.W.; Kartvelishvily, E.; Tohya, K.; Miyasaka, M.; Alon, R.; Haran, G. Three-dimensional localization of T-cell receptors in relation to microvilli using a combination of super resolution microscopies. Proc. Natl. Acad. Sci. USA 2016, 113, E5916–E5924.